The analysis of succinate dehydrogenase and lactate dehydrogenase activity in acute and chronic hypoxia on the background of 2-benzamide-2-(2-oxoindolin-3-ylidene) acetic acid derivative administration

Authors

DOI:

https://doi.org/10.15587/2519-4852.2017.98164

Keywords:

antihypoxants, succinate dehydrogenase, lactate dehydrogenase, hypoxia, 2-benzamide-2-(2-oxoindolin-3-ylidene) acetic acid derivatives, Mexidol

Abstract

Aim. To study the influence of 2-benzamide-2-(2-oxoindolin-3-ylidene) acetic acid derivative ZNM on succinate dehydrogenase and lactate dehydrogenase activity biochemical markers of energy metabolism and hypoxia in the rats’ brain under acute hypobaric hypoxia (AHH) and normobaric hypercapnic hypoxia (NHH), as well as chronic hypobaric hypoxia (CHH).

Materials and methods. 80 white nonlinear mature male rats 180-200 g in weight were used for research. AHH was modeled using flowing altitude chamber by stimulation the effect of12000 m altitude “ascending” in rats. The rats were kept at the "high-altitude plateau" till the moment of the second agonal inspiration, then the “descent” to the previous zero height was performed.

NHH was reproduced by placing the rats into a sealed chamber, 1000 ml capacity, and then duration of stay of the rats in a closed chamber from the moment of container closing till the second agonal inspiration was estimated.

CHH was modeled in the flowing altitude chamber by stimulation the effect of4000 maltitude above sea “ascending” in rats. The animals were kept at this “height” during 2 hours every day within 4 weeks; hypoxia sessions were carried out before midday.

The studied substances were administered intraperitoneally 35 minutes before hypoxia modeling. The studied substance ZNM was administered in the dose of 15 mg/kg as water suspension, stabilized with Polysorbate 80. The reference drug Mexidol was administered in the dose of 100 mg/kg. The intact animals took an equivalent amount of water for injection with Polysorbate 80. The group of animals with stimulated CHH was treated by the remedies after 14th day of hypoxia modeling.

Results. The activity of succinate dehydrogenase after ZNM administration, depending on the hypoxia type, significantly increased in the AHH group in 2.6 times, and in the NHH group – in 1.6 times comparing to the model pathology group. After Mexidol administration, the activity markers raised in the AHH group in 2.9 times, NHH – 1.7 times, CHH – in 1.3 times.

At the same time, the activity of lactate dehydrogenase after ZNM and Mexidol administration decreased in the AHH group in 1.5 times, NHH – in 1.3 times (in 1.5 times after Mexidol administration). Under CHH conditions, the activity of lactate dehydrogenase after Mexidol administration stayed unchanged, and after ZNM administration it slightly but statistically significantly decreased by 7.5% compared to the model pathology indexes.

Conclusion. ZNM substance and the reference drug Mexidol normalize activity of succinate dehydrogenase and lactate dehydrogenase, which indicates the improvement of energy metabolism of cells in acute and chronic hypoxia

Author Biographies

Іgor Zamorskii, Bukovinian State Medical University Teatralna sq., 2, Chernivtsi, Ukraine, 58002

MD, Professor

Department of Pharmacology

Yuliana Bukataru, Bukovinian State Medical University Teatralna sq., 2, Chernivtsi, Ukraine, 58002

Department of Pharmacology

Svitlana Melnychuk, Bukovinian State Medical University Teatralna sq., 2, Chernivtsi, Ukraine, 58002

PhD

Department of Pharmacology

References

  1. Usenko, L. V., Tsariov, O. V. (2016). Modern Opportunities of Energy Protection in Critical States. Emergency medicine, 4 (75), 72–78. doi: 10.22141/2224-0586.4.75.2016.75820
  2. Novykov, V. E., Levchenkova, O. S. (2013). Novye napravlenyya poyska lekarstvennykh sredstv s antyhypoksycheskoy aktyvnostʹyu y mysheny dlya ykh deystvyya. Eksperymentalʹnaya y klynycheskaya farmakolohyya, 76 (5), 37–47.
  3. Levchenkova, O. S., Novykov, V. E., Pozhylova, E. V. (2012). Farmakodynamyka y klynycheskoe prymenenye antyhypoksantov. Obzory po klynycheskoy farmakolohyy y lekarstvennoy terapyy, 10 (3), 3–12.
  4. Rukan, T. A., Maksymovych, N. E., Zymatkyn, S. M. (2013). Aktyvnostʹ nekotorykh fermentov v neyronakh frontalʹnoy kory holovnoho moz·ha krys v rannyy postyshemycheskyy peryod. Vestnyk VNMU, 12 (2), 50–54.
  5. Tsubanova, N. A., Shtryhol, S. Yu., Horbach, T. V. (2012). Vplyv spirotsyklichnoho pokhidnoho oksindolu na pokaznyky tserebralʹnoho enerhetychnoho obminu v umovakh hipoksychnoyi ta nehipoksychnoyi patolohiyi. Klinichna farmatsiya, 16 (4), 51–54.
  6. Kolisnyk, S. V., Kononenko, N. P., Haman, D. V., Kotenko, O. M. (2011). Zv'yazok "struktura-antyhipoksychna aktyvnistʹ" u ryadu pokhidnykh 2-benzamido-2-(2-oksoindoliniliden-3)-otstovoyi kysloty. Visnyk farmatsiyi, 4, 64–66.
  7. Zamorskii, I. I., Bukataru, Yu. S., Lenga, E. L., Kolisnyk, S. V., Altukhov, О. О. (2016). Screening of derivatives of 2-(benzoyilamino)(1-r-2-oxoindolin-3-ylidene)acetic acid under the conditions of acute hypobaric hypoxia. News of pharmacy, 1, 67–70.
  8. Vazhnycha, O. M. (2001). Antystresorna aktyvnistʹ meksydolu i rolʹ strukturnykh komponentiv preparatu v yiyi realizatsiyi. Klinichna farmatsiya, 5 (2), 60–63.
  9. Poshuk i eksperementalʹne vyvchennya potentsiynykh protyhipoksychnykh zasobiv (2002). Kyiv: Ministerstvo okhorony zdorovʺya. Derzhavnyy farmakolohichnyy tsentr, 27.
  10. Pasevych, S. P., Zamorsʹkyy, I. I. (2014). Antyoksydantnyy potentsial pokhidnykh 3-oksypirydynu za umov khronichnoyi hipoksychnoyi hipoksiyi. Ukrayinsʹkyy biofarmatsevtychnyy zhurnal, 5, 9–12.
  11. Kamyshnykov, V. S. (2009). Spravochnyk po klynyko-byokhymycheskym yssledovanyyam y laboratornoy dyahnostyke. Moscow: MEDpress-ynform, 896.

Downloads

Published

2017-04-29

How to Cite

Zamorskii І., Bukataru, Y., & Melnychuk, S. (2017). The analysis of succinate dehydrogenase and lactate dehydrogenase activity in acute and chronic hypoxia on the background of 2-benzamide-2-(2-oxoindolin-3-ylidene) acetic acid derivative administration. ScienceRise: Pharmaceutical Science, (2 (6), 9–13. https://doi.org/10.15587/2519-4852.2017.98164

Issue

No. 2 (6) (2017)

Section

Pharmaceutical Science

License

Copyright (c) 2017 Іgor Zamorskii, Yuliana Bukataru, Svitlana Melnychuk

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons Attribution 4.0 International License copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.

3. Authors have the right to store the final accepted version of the article in an institutional, thematic, or any other repository to ensure visibility and accessibility.